TEST:

DecisionDx® DiffDx-Melanoma

"Castle Biosciences, Inc...announced that new data supporting the clinical value of the Company’s skin cancer test portfolio is being shared in poster presentations at the 2023 Winter Clinical Dermatology Conference - Hawaii®, being held Jan. 13-18 in Kohala Coast, Hawaii."

Investor Presentation

"Castle Biosciences, Inc....announced a recent poster presentation showcasing the performance of its diagnostic gene expression profile (GEP) test, DiffDx^®-Melanoma....In the case study presented during the College of American Pathologists 2022 (CAP22) Annual Meeting, DiffDx-Melanoma supported the need to perform a local excision on a difficult-to-diagnose melanocytic lesion after clinicopathological correlation was not achieved by dermoscopy, reflectance confocal microscopy and/or histopathological assessment alone."

"Castle Biosciences, Inc...provided a proposed framework of the Company’s diagnostic gene expression profile (GEP) tests, MyPath^® Melanoma and DiffDx^®-Melanoma, for use in clinical practice to help achieve personalized management and treatment plans....Additionally, the poster shares impactful data demonstrating how benign and malignant diagnostic GEP test results can alter patient management plans, including: a 76.7%-80.5% reduction in excisions for patients with benign test results, and a 75% increase in excisions for patients with malignant results; and; 74.1% of dermatologists reducing office visits for patients with benign test results, and 95.2% of dermatologists increasing office visits for patients with malignant results."